Abstract：
BACKGROUND: Personalized medicine poses great opportunities and challenges. While the therapeutic landscape markedly expands, descriptions about status, clinical implementation and real-world benefits of precision oncology and molecular tumor boards (MTB) remain sparse, particularly in the field of genitourinary (GU) cancer. Hence, this study characterized urological MTB cases to better understand the potential role of MTB in uro-oncology.
METHODS: We analyzed patients with complete data sets being reviewed at an MTB from January 2019 to October 2022, focusing on results of molecular analysis and treatment recommendations.
RESULTS: We evaluated 102 patients with GU cancer with a mean patient age of 61.7 years. Prostate cancer (PCa) was the most frequent entity with 52.9% (54/102), followed by bladder cancer (18.6%, 19/102) and renal cell carcinoma (14.7%, 15/102). On average, case presentation at MTB took place 54.9 months after initial diagnosis and after 2.7 previous lines of therapy. During the study period, 49.0% (50/102) of patients deceased. Additional MTB-based treatment recommendations were achieved in a majority of 68.6% (70/102) of patients, with a recommendation for targeted therapy in 64.3% (45/70) of these patients. Only 6.7% (3/45) of patients - due to different reasons - received the recommended MTB-based therapy though, with 33% (1/3) of patients reaching disease control. Throughout the MTB study period, GU cancer case presentations and treatment recommendations increased, while the time interval between initial presentation and final therapy recommendation were decreasing over time.
CONCLUSIONS: Presentation of uro-oncological patients at the MTB is a highly valuable measure for clinical decision-making. Prospectively, earlier presentation of patients at the MTB and changing legislative issues regarding comprehensive molecular testing and targeted treatment approval might further improve patients\' benefits from comprehensive molecular diagnostics.
METHODS: We analyzed patients with complete data sets being reviewed at an MTB from January 2019 to October 2022, focusing on results of molecular analysis and treatment recommendations.
RESULTS: We evaluated 102 patients with GU cancer with a mean patient age of 61.7 years. Prostate cancer (PCa) was the most frequent entity with 52.9% (54/102), followed by bladder cancer (18.6%, 19/102) and renal cell carcinoma (14.7%, 15/102). On average, case presentation at MTB took place 54.9 months after initial diagnosis and after 2.7 previous lines of therapy. During the study period, 49.0% (50/102) of patients deceased. Additional MTB-based treatment recommendations were achieved in a majority of 68.6% (70/102) of patients, with a recommendation for targeted therapy in 64.3% (45/70) of these patients. Only 6.7% (3/45) of patients - due to different reasons - received the recommended MTB-based therapy though, with 33% (1/3) of patients reaching disease control. Throughout the MTB study period, GU cancer case presentations and treatment recommendations increased, while the time interval between initial presentation and final therapy recommendation were decreasing over time.
CONCLUSIONS: Presentation of uro-oncological patients at the MTB is a highly valuable measure for clinical decision-making. Prospectively, earlier presentation of patients at the MTB and changing legislative issues regarding comprehensive molecular testing and targeted treatment approval might further improve patients\' benefits from comprehensive molecular diagnostics.
摘要：
目的：个性化医疗带来了巨大的机遇和挑战。虽然治疗前景明显扩大，关于状态的描述，精确肿瘤学和分子肿瘤委员会（MTB）的临床实施和现实世界的好处仍然很少，特别是在泌尿生殖系统（GU）癌症领域。因此，本研究以泌尿系MTB病例为特征,以更好地了解MTB在泌尿系肿瘤学中的潜在作用.
方法：我们分析了2019年1月至2022年10月在MTB审查的完整数据集的患者，重点是分子分析和治疗建议的结果。
结果：我们评估了102例GU癌症患者，患者平均年龄为61.7岁。前列腺癌（PCa）是最常见的实体，占52.9％（54/102），其次是膀胱癌（18.6%，19/102）和肾细胞癌（14.7％，15/102)。平均而言,MTB的病例报告发生在初次诊断后54.9个月和之前2.7行治疗后.在研究期间49.0%(50/102)的患者死亡。68.6%(70/102)的患者获得了额外的基于MTB的治疗建议，其中64.3%(45/70)的患者推荐靶向治疗.只有6.7％（3/45）的患者-由于不同的原因-接受推荐的基于MTB的治疗艰难，33%(1/3)的患者达到疾病控制。在整个MTB研究期间，GU癌症病例报告和治疗建议增加，而初始治疗和最终治疗建议之间的时间间隔随着时间的推移而减少.
结论：在MTB中介绍泌尿肿瘤患者是临床决策的非常有价值的措施。Prospective,在MTB中更早地介绍患者,以及在全面分子检测和靶向治疗批准方面不断变化的立法问题,可能会进一步改善患者从全面分子诊断中获益.
方法：我们分析了2019年1月至2022年10月在MTB审查的完整数据集的患者，重点是分子分析和治疗建议的结果。
结果：我们评估了102例GU癌症患者，患者平均年龄为61.7岁。前列腺癌（PCa）是最常见的实体，占52.9％（54/102），其次是膀胱癌（18.6%，19/102）和肾细胞癌（14.7％，15/102)。平均而言,MTB的病例报告发生在初次诊断后54.9个月和之前2.7行治疗后.在研究期间49.0%(50/102)的患者死亡。68.6%(70/102)的患者获得了额外的基于MTB的治疗建议，其中64.3%(45/70)的患者推荐靶向治疗.只有6.7％（3/45）的患者-由于不同的原因-接受推荐的基于MTB的治疗艰难，33%(1/3)的患者达到疾病控制。在整个MTB研究期间，GU癌症病例报告和治疗建议增加，而初始治疗和最终治疗建议之间的时间间隔随着时间的推移而减少.
结论：在MTB中介绍泌尿肿瘤患者是临床决策的非常有价值的措施。Prospective,在MTB中更早地介绍患者,以及在全面分子检测和靶向治疗批准方面不断变化的立法问题,可能会进一步改善患者从全面分子诊断中获益.
